Bioadaptives (BDPT) Liabilities and Shareholders Equity (2013 - 2026)

Bioadaptives has disclosed Liabilities and Shareholders Equity across 13 years of filings, most recently posting $135949.0 for Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $135949.0, up 23.09% year-over-year; the trailing twelve-month figure through Mar 2026 was $758725.0 (up 77.5% YoY), and the FY2025 annual result was $225901.0, down 13.74% from the prior year.
• Liabilities and Shareholders Equity came in at $135949.0 for Q1 2026 at Bioadaptives, down from $225901.0 in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $329302.0 in Q3 2023 to a low of $8735.0 in Q2 2024.
• The 5-year median for Liabilities and Shareholders Equity is $87072.0 (2022), against an average of $115461.4.
• Across the five-year window, Liabilities and Shareholders Equity plunged 85.91% in 2024 and soared 3019.81% in 2025, its largest moves.
• Bioadaptives' Liabilities and Shareholders Equity stood at $37314.0 in 2022, then jumped by 178.71% to $103998.0 in 2023, then jumped by 151.82% to $261885.0 in 2024, then dropped by 13.74% to $225901.0 in 2025, then slumped by 39.82% to $135949.0 in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $135949.0 (Q1 2026), $225901.0 (Q4 2025), and $124360.0 (Q3 2025), per Business Quant data.